Compare Cytokinetics Inc (CYTK) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Gold Fields Limited — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Gold Fields Limited trades at $32.48 (market cap $29.97B). The key difference: Gold Fields Limited is far larger — about 2.7× Cytokinetics Inc's market cap, and Gold Fields Limited pays a 6.96% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | GFI | |
|---|---|---|
Market Cap | $11.12B | $29.97B |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $61.52 |
52-Week Low | $33.23 | $23.95 |
Enterprise Value | $11.59B | $31.41B |
Dividend Yield | — | 6.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Gold Fields (GFI) trades at $33.53, down 1.79% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with a P/E of 8.51, net income margin of 40.76%, and robust ROE of 52.33%. Recent earnings were mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and revenue growth accelerated to $8.8B. Analyst consensus is a Buy with a $52.75 price target, though recent news highlights operational cost pressures.
The outlook for GFI is positive based on valuation and profitability, but near-term risks include cost inflation and gold price volatility. The stock offers value with upside to analyst targets, supported by strong cash generation and a shareholder-friendly dividend policy. Key risks are execution at mines and macroeconomic factors affecting gold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
